The SMART CART Study: Health Information Technology

Status Completed

Clinical Trial Summary

This study evaluates the feasibility of using two information technology tools in patients undergoing Chimeric Antigen Receptor T-cell (CART) therapy and other Cytokine Release Syndrome (CRS)-eliciting treatments such as CD123 BITE. The first is an Apple iPad® application called the BMT Roadmap, which shows information about the participant's health. The second is a wearable activity monitoring device. Health information technology tools such as Roadmap system and the activity monitoring device may enable caregivers and patients to become more active participants in their healthcare.

Clinical Trial Description

100 patients will be asked to participate in the wearable device portion of the study. 100 caregivers will be asked to participate in the Roadmap (iPad) portion of the study. Each caregiver will be provided with an iPad to use the BMT Roadmap system. Patients and/or caregivers are free to use this tool as much as they would like on their own time while in the hospital. The hospital care team will collect the iPad when the patient is discharged and ready to go home. Patients and caregivers will also be asked to take three surveys that will ask about their feelings and thoughts about the Roadmap application. The surveys will be completed when patients are admitted for their CART or other CRS-eliciting therapy, when they get discharged from the hospital and around 100 days after they receive their therapy. In addition to the use of the BMT Roadmap, this study will include around 7-10 interviews about participants' opinions on the two tools and their experience in the therapy process. ;

Study Design

Related Conditions & MeSH terms

Leukemia
Leukemia, Acute
Leukemia, Lymphoblastic
Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trial Details

NCT number	NCT04051216
Study type	Interventional
Source	University of Michigan Rogel Cancer Center
Contact
Status	Completed
Phase	N/A
Start date	December 20, 2017
Completion date	November 23, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03680677` - Frailty Phenotype Assessments to Optimize Treatment Strategies for Older Patients With Hematologic Malignancies
Completed	`NCT04194086` - Population Pharmacokinetics and Safety of Oral Posaconazole in Children With Leukemia	Phase 1/Phase 2
Completed	`NCT04710212` - Screening for Colonization With Resistant Enterobacterales in Neutropenic Patients With Hematologic Malignancies
Terminated	`NCT01050764` - Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells	Phase 1/Phase 2
Completed	`NCT03434704` - Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole	Phase 2
Recruiting	`NCT05823571` - Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients	Phase 1
Completed	`NCT04236063` - Rehabilitation Needs of the Malaysian Haematological Cancer Survivors
Completed	`NCT04745416` - Clinical Characteristics of Patients With Leukemia and COVID-19
Not yet recruiting	`NCT03336632` - Chidamide Plus PTCy/Cyclosporine to Prevent GVHD After Myeloablative Conditioning, Matched PBSCT	Phase 2
Completed	`NCT05969600` - The Relapses in Childhood Acute Lymphoplastic Leukemia Excluding L3
Recruiting	`NCT06335277` - Total Body Irradiation Treatments for Patients Treated at European Institute of Oncology
Recruiting	`NCT03564704` - Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult T-LBL/ALL	Phase 2/Phase 3
Recruiting	`NCT03564470` - Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL	Phase 2/Phase 3
Recruiting	`NCT03553238` - Precision Diagnosis Directing HDACi Chidamide Target Therapy for Adult ETP-ALL	Phase 2/Phase 3
Terminated	`NCT03963024` - Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT	Phase 1
Completed	`NCT03297476` - Clinical Application of Novel Panels for Early Precision Diagnosis and Relapse Prediction in High-risk Leukemia
Recruiting	`NCT04482894` - Palliative Care Oncology in Patients With Relapsed, Refractory, and High-Risk Leukemias or MDS	Phase 2
Recruiting	`NCT05236296` - Emotion and Symptom-focused Engagement for Caregivers (EASE-CG) Pilot Study	N/A